

# Francesco Cosentino

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5730282/francesco-cosentino-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199  
papers

16,453  
citations

54  
h-index

127  
g-index

223  
ext. papers

21,047  
ext. citations

6.6  
avg, IF

6.44  
L-index

#	Paper	IF	Citations
199	The year in cardiovascular medicine 2021: diabetes and metabolic disorders.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	2
198	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).. <i>Diabetes Therapy</i> , <b>2022</b> , 13, 795	3.6	1
197	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].. <i>Diabetologia</i> , <b>2022</b> , 65, 908	10.3	
196	Guideline Development for Medical Device Technology: Issues for Consideration.. <i>Journal of Diabetes Science and Technology</i> , <b>2022</b> , 19322968221093355	4.1	
195	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 787761	5.4	13
194	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 218	8.7	7
193	Vascular repair and regeneration in cardiometabolic diseases. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	1
192	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , <b>2021</b> , 64, 1256-1267	10.3	28
191	Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1012-1022	12.3	10
190	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 139-140	18.1	1
189	Kidney outcomes using a sustained 40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 1139-1143	3.3	6
188	Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 1345-1354	6.9	4
187	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1260-1275	12.3	12
186	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 29-42	9.9	53
185	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 46-52	18.1	34
184	Investigating the possible impact of peritoneal tumor exposure amongst women with early stage cervical cancer treated with minimally invasive approach. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1090-1097	3.6	10
183	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 148-158	16.2	194

182	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV. <i>Circulation</i> , <b>2021</b> , 143, 602-605	16.7	11
181	Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 845-852	4.9	2
180	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2021</b> , 7, 28-33	4.6	1
179	The year in cardiovascular medicine 2020: epidemiology and prevention. <i>European Heart Journal</i> , <b>2021</b> , 42, 813-821	9.5	13
178	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	7
177	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108870	7.4	1
176	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , <b>2021</b> , 42, 3227-3337	9.5	358
175	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	31
174	A Multicentric Randomized Trial to Evaluate the ROle of Uterine MANipulator on Laparoscopic/Robotic HYsterectomy for the Treatment of Early-Stage Endometrial Cancer: The ROMANHY Trial. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 720894	5.3	0
173	Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019918	6	1
172	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , <b>2021</b> , 17, e618-e630	3.1	0
171	SGLT2i: new perspectives in diabetes and kidney disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, e4	6.4	
170	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , <b>2020</b> , 313, 76-82	3.2	9
169	Diabetes and coronary artery disease: not just a risk factor. <i>Heart</i> , <b>2020</b> , 106, 1357-1364	5.1	4
168	Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
167	High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320911845	3.9	2
166	Laparoscopic treatment of ovarian granulosa cells tumor developed in the pelvic anterior preperitoneal space 20 years after laparotomic salpingo-oophorectomy: case report and review of literature. <i>Gynecological Endocrinology</i> , <b>2020</b> , 36, 926-928	2.4	4
165	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1495-1503	12.3	56

164	Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer. <i>Chemotherapy</i> , <b>2020</b> , 65, 54-57	3.2	1
163	Feasibility and safety of two different surgical routes for the eradication of recto-vaginal endometriosis with vaginal mucosa infiltration (Endo-Vag-r study). <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2020</b> , 99, 1050-1056	3.8	5
162	Prevention and treatment of venous thromboembolism. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, C1	1.5	
161	Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 712-713	3.5	2
160	The year in cardiology: cardiovascular prevention /The year in cardiology 2019. <i>Revista Romana De Cardiologie</i> , <b>2020</b> , 30, 20-29	0.1	
159	Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 1687-2	3.2	3
158	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , <b>2020</b> , 14, 998	2.7	2
157	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 149-157	6.7	13
156	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , <b>2020</b> , 41, 1157-1163	9.5	12
155	How to Select Early-Stage Cervical Cancer Patients Still Suitable for Laparoscopic Radical Hysterectomy: a Propensity-Matched Study. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1947-1955	3.1	41
154	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 196-213	12.3	85
153	Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 329-330	9.5	8
152	Long-term evaluation of quality of life and gastrointestinal well-being after segmental colo-rectal resection for deep infiltrating endometriosis (ENDO-RESECT QoL). <i>Archives of Gynecology and Obstetrics</i> , <b>2020</b> , 301, 217-228	2.5	11
151	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. <i>Circulation</i> , <b>2020</b> , 142, 2205-2215	16.7	77
150	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1984-1986	12.3	44
149	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1657-1664	3.5	63
148	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1425-1435	59.2	418
147	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3438	3.7	6

146	The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. <i>European Heart Journal</i> , <b>2020</b> , 41, 3419-3420	9.5	3
145	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , <b>2020</b> , 127, 1261-1273	15.7	12
144	High-intensity interval training modulates retinal microvascular phenotype and DNA methylation of p66Shc gene: a randomized controlled trial (EXAMIN AGE). <i>European Heart Journal</i> , <b>2020</b> , 41, 1514-1519	9.5	22
143	Physical activity may drive healthy microvascular ageing via downregulation of p66. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 168-176	3.9	9
142	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , <b>2020</b> , 41, 255-323	9.5	1360
141	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320912491	9.5	7
140	Arterial-enteric fistula after pelvic lymphadenectomy in secondary cytoreductive surgery for recurrent ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , <b>2019</b> , 39, 1049-1056	1.3	7
139	The environment, epigenetic landscape and cardiovascular risk. <i>Cardiovascular Research</i> , <b>2019</b> , 115, e1479-1501	9.5	1501
138	The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, C37-C39	1.5	
137	The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the Ten Commandments of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen. <i>European Heart Journal</i> , <b>2019</b> , 40, 3215-3217	9.5	78
136	Exercise-induced improvement of microvascular phenotype and reprogramming of p66Shc DNA methylation. <i>European Heart Journal</i> , <b>2019</b> , 40, 3948-3949	9.5	3
135	Cardio-diabetology: The new 'sweetheart' in cardiovascular prevention. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 5-6	3.9	0
134	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , <b>2019</b> , 40, 2907-2919	9.5	22
133	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , <b>2019</b> , 40, 336-344	9.5	14
132	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , <b>2019</b> , 40, 383-391	9.5	33
131	Robotic versus laparoscopic radical hysterectomy in early cervical cancer: A case matched control study. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 754-759	3.6	41
130	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 853-872	12.3	264
129	Glucose-lowering treatment in cardiovascular and peripheral artery disease. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 39, 86-98	5.1	4

128	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 377-387	3.9	8
127	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 246-256	7.9	22
126	Diabetes and ischaemic stroke: a deadly association. <i>European Heart Journal</i> , <b>2018</b> , 39, 2387-2389	9.5	3
125	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , <b>2018</b> , 39, 345-353	9.5	3
124	Near-Infrared Imaging with Indocyanine Green for Detection of Endometriosis Lesions (Gre-Endo Trial): A Pilot Study. <i>Journal of Minimally Invasive Gynecology</i> , <b>2018</b> , 25, 1249-1254	2.2	29
123	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. <i>Diabetes and Vascular Disease Research</i> , <b>2018</b> , 15, 14-23	3.3	11
122	Epigenetics and Immunometabolism in Diabetes and Aging. <i>Antioxidants and Redox Signaling</i> , <b>2018</b> , 29, 257-274	8.4	43
121	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66. <i>International Journal of Cardiology</i> , <b>2018</b> , 268, 179-186	3.2	32
120	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , <b>2018</b> , 39, 4243-4254	9.5	113
119	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , <b>2018</b> , 206, 11-23	4.9	139
118	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 2814-2821	6.9	60
117	Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1062-1068	3.6	22
116	Laparoscopic Management of Abdominal Pregnancy. <i>Journal of Minimally Invasive Gynecology</i> , <b>2017</b> , 24, 724-725	2.2	10
115	Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 52-60	3.9	30
114	Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1068-1075	2.4	1
113	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA Levels. <i>Diabetes</i> , <b>2017</b> , 66, 2472-2482	9.9	105
112	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , <b>2016</b> , 37, 152-60	9.5	21
111	Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>European Journal of Cancer</i> , <b>2016</b> , 59, 22-33	7.5	203

110	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 702-7	3.2	35
109	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , <b>2016</b> , 37, 1733-7	9.5	22
108	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , <b>2016</b> , 37, 572-6	9.5	102
107	Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 214, 503.e1-503.e6	6.4	40
106	Telelap ALF-X vs Standard Laparoscopy for the Treatment of Early-Stage Endometrial Cancer: A Single-Institution Retrospective Cohort Study. <i>Journal of Minimally Invasive Gynecology</i> , <b>2016</b> , 23, 378-83 <sup>2.2</sup>		42
105	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , <b>2016</b> , 594, 2061-73	3.9	164
104	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , <b>2016</b> , 18, C2-C12	1.5	56
103	Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. <i>Circulation: Cardiovascular Genetics</i> , <b>2015</b> , 8, 150-8		106
102	Diabetic Dyslipidemia <b>2015</b> , 101-113		1
101	Hyperglycemia <b>2015</b> , 85-100		
100	Diabetes and Cardiovascular Disease <b>2015</b> , 13-21		
99	Molecular pathways of arterial aging. <i>Clinical Science</i> , <b>2015</b> , 128, 69-79	6.5	31
98	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. <i>Atherosclerosis</i> , <b>2015</b> , 241, 507-32	3.1	420
97	Epidemiology, Definition, and Diagnosis of Diabetes Mellitus <b>2015</b> , 3-12		2
96	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. <i>Atherosclerosis Supplements</i> , <b>2015</b> , 19, 1-12	1.7	50
95	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , <b>2015</b> , 36, 817-28	9.5	57
94	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , <b>2015</b> , 199, 415-23	3.2	7
93	Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. <i>Current Pharmaceutical Biotechnology</i> , <b>2015</b> , 16, 531-43	2.6	24

92	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2015</b> , 5, 403-6	2.6	12
91	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , <b>2015</b> , 6, 326-32	4.7	43
90	Mechanisms of Diabetic Atherosclerosis <b>2015</b> , 23-33		1
89	Risk Stratification <b>2015</b> , 69-83		
88	Ischemic Stroke <b>2015</b> , 189-202		
87	Environment, Epigenetic Changes, and Cardiovascular Damage <b>2015</b> , 35-47		
86	Antiplatelet Therapy <b>2015</b> , 133-144		
85	Arterial Hypertension <b>2015</b> , 115-131		
84	Non-coronary atherosclerosis. <i>European Heart Journal</i> , <b>2014</b> , 35, 1112-9	9.5	95
83	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Española De Cardiología</i> , <b>2014</b> , 67, 136.e1-136.e56	1.5	8
82	Insulin resistance, diabetes, and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 419	6	99
81	p66(Shc)-induced redox changes drive endothelial insulin resistance. <i>Atherosclerosis</i> , <b>2014</b> , 236, 426-9	3.1	23
80	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. <i>Diabetes and Vascular Disease Research</i> , <b>2014</b> , 11, 133-73	3.3	137
79	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2014</b> , 4, 324-32	2.6	22
78	Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. <i>Atherosclerosis</i> , <b>2013</b> , 230, 191-7	3.1	54
77	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , <b>2013</b> , 34, 2444-52	9.5	213
76	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2013</b> , 34, 3035-87	9.5	1444
75	Mechanisms of Cardiovascular Aging. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , <b>2013</b> , 2, 275-283		1



74	Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. <i>Circulation</i> , <b>2013</b> , 127, 1229-40, e1-21	16.7	73
73	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. <i>European Heart Journal</i> , <b>2013</b> , 34, 2436-43	9.5	597
72	SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. <i>Diabetes</i> , <b>2013</b> , 62, 1800-7	0.9	73
71	Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , <b>2013</b> , 34, 96-103	9.5	56
70	Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. <i>Atherosclerosis</i> , <b>2012</b> , 220, 282-6	3.1	43
69	The clinical relevance of dysfunctional HDL in patients with coronary artery disease: a 3-year follow-up study. <i>International Journal of Cardiology</i> , <b>2012</b> , 158, 158-60	3.2	5
68	p66 Shc as the engine of vascular aging. <i>Current Vascular Pharmacology</i> , <b>2012</b> , 10, 697-9	3.3	18
67	Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. <i>Circulation Research</i> , <b>2012</b> , 111, 278-89	15.7	169
66	Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 1399-405	1.9	101
65	Anti-aging medicine: molecular basis for endothelial cell-targeted strategies - a mini-review. <i>Gerontology</i> , <b>2011</b> , 57, 101-8	5.5	27
64	Is there any memory effect of blood pressure lowering in diabetes?. <i>International Journal of Cardiology</i> , <b>2011</b> , 151, 384-5	3.2	2
63	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2011</b> , 32, 2851-907	9.5	1126
62	Is early stage endometrial cancer safely treated by laparoscopy? Complications of a multicenter study and review of recent literature. <i>Surgical Oncology</i> , <b>2011</b> , 20, 80-7	2.5	26
61	Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. <i>Current Hypertension Reports</i> , <b>2011</b> , 13, 318-24	4.7	25
60	Prevalence of 'borderline' values of cardiovascular risk factors in the clinical practice of general medicine in Italy: results of the BORDERLINE study. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2011</b> , 18, 43-51	2.9	3
59	Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 2090-7	9.4	79
58	Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2011</b> , 18, 775-89		203
57	The Role of Oxidative Stress in Endothelial Dysfunction and Vascular Inflammation <b>2010</b> , 705-754		7

56	Alzheimer's disease and endothelial dysfunction. <i>Neurological Sciences</i> , <b>2010</b> , 31, 1-8	3.5	32
55	Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. <i>European Heart Journal</i> , <b>2009</b> , 30, 1301-4	9.5	4
54	Impact of fasting glycemia and regional cerebral perfusion in diabetic subjects: a study with technetium-99m-ethyl cysteinyl dimer single photon emission computed tomography. <i>Stroke</i> , <b>2009</b> , 40, 306-8	6.7	22
53	Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer: a prospective randomized study. <i>Gynecologic Oncology</i> , <b>2009</b> , 112, 126-33	4.9	139
52	p66(Shc) protein, oxidative stress, and cardiovascular complications of diabetes: the missing link. <i>Journal of Molecular Medicine</i> , <b>2009</b> , 87, 885-91	5.5	43
51	Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. <i>Clinical and Experimental Hypertension</i> , <b>2008</b> , 30, 616-27	2.2	26
50	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2008</b> , 15, 17-22	2.9	1
49	Inhibition of protein kinase C $\beta$ prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. <i>Circulation</i> , <b>2008</b> , 118, 2174-82	16.7	39
48	c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. <i>Circulation</i> , <b>2008</b> , 118, 2073-80	16.7	76
47	The role of p66Shc deletion in age-associated arterial dysfunction and disease states. <i>Journal of Applied Physiology</i> , <b>2008</b> , 105, 1628-31	3.7	46
46	Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 622-8	9.4	138
45	Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 5217-22	11.5	205
44	Restoring the dysfunctional endothelium. <i>Current Pharmaceutical Design</i> , <b>2007</b> , 13, 1053-68	3.3	33
43	Diabetes and Endothelial Dysfunction. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2007</b> , 14, 5-10	2.9	2
42	Effects of Olmesartan on Endothelial Function. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2007</b> , 14, 221-227	2.9	1
41	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2007</b> , 28, 88-136	9.5	889
40	The Role of eNOS in Vascular Diseases <b>2007</b> , 227-243		
39	Aging and endothelial dysfunction. <i>Clinical Hemorheology and Microcirculation</i> , <b>2007</b> , 37, 143-7	2.5	8

38	Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. <i>Journal of Cardiovascular Pharmacology</i> , <b>2006</b> , 47, 663-7	3.1	3
37	Nitric oxide release is impaired in hypertensive individuals with familial history of stroke. <i>American Journal of Hypertension</i> , <b>2006</b> , 19, 1213-6	2.3	6
36	Antioxidants and Endothelial Function: Human Studies. <i>Developments in Cardiovascular Medicine</i> , <b>2006</b> , 279-304		
35	Viewpoint: Climbing the academic ladder in Italy. <i>Circulation</i> , <b>2006</b> , 114, f193-4	16.7	1
34	The Renin-Angiotensin System, Capri 2005. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2005</b> , 12, 91-108	2.9	
33	Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, 493-9	3.3	92
32	Hypertension, stroke, and endothelium. <i>Current Hypertension Reports</i> , <b>2005</b> , 7, 68-71	4.7	27
31	Glycogen synthase kinase-3 mediates endothelial cell activation by tumor necrosis factor-alpha. <i>Circulation</i> , <b>2005</b> , 112, 1316-22	16.7	47
30	Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. <i>Cardiovascular Drug Reviews</i> , <b>2004</b> , 22, 155-68		42
29	Deletion of p66shc gene protects against age-related endothelial dysfunction. <i>Circulation</i> , <b>2004</b> , 110, 2889-95	16.7	252
28	Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. <i>Circulation</i> , <b>2004</b> , 110, 91-6	16.7	105
27	Diabetes and inflammation. <i>Herz</i> , <b>2004</b> , 29, 749-59	2.6	21
26	Protocol for an Observational Blood Pressure Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2004</b> , 11, 11-14	2.9	2
25	High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. <i>Circulation</i> , <b>2003</b> , 107, 1017-23	16.7	346
24	Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy. <i>Journal of Hypertension</i> , <b>2003</b> , 21, 501-3	1.9	1
23	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. <i>Circulation</i> , <b>2003</b> , 108, 1527-32	16.7	982
22	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. <i>Circulation</i> , <b>2003</b> , 108, 1655-61	16.7	342
21	Oxidative Stress and Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2003</b> , 10, 27-33	2.9	

20	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2003</b> , 10, 81-86	2.9	5
19	Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 1721-4	1.9	2
18	Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. <i>Circulation</i> , <b>2002</b> , 105, 1756-9	16.7	295
17	Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 421-8	1.9	44
16	AT2-mediated vasorelaxation by angiotensin II in SHR chronically treated with losartan. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, A13	2.3	
15	Effects of blood pressure and glucose on endothelial function. <i>Current Hypertension Reports</i> , <b>2001</b> , 3, 79-88	4.7	30
14	Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2001</b> , 21, 496-502	9.4	146
13	Endothelial dysfunction and stroke. <i>Journal of Cardiovascular Pharmacology</i> , <b>2001</b> , 38 Suppl 2, S75-8	3.1	45
12	Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. <i>Journal of Cardiovascular Pharmacology</i> , <b>2001</b> , 38 Suppl 3, S3-11	3.1	14
11	Nifedipine inhibits superoxide production induced by pulsatile stretch in human aortic endothelial cells. <i>American Journal of Hypertension</i> , <b>2000</b> , 13, S34	2.3	0
10	Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, S45-48	3.1	28
9	Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, 173-8	3.1	170
8	Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 36, 316-20	3.1	38
7	Atherosclerosis and the two faces of endothelial nitric oxide synthase. <i>Circulation</i> , <b>1998</b> , 97, 108-12	16.7	246
6	Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats. <i>Journal of Hypertension</i> , <b>1998</b> , 16, 151-6	1.9	10
5	High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. <i>Circulation</i> , <b>1997</b> , 96, 25-8	16.7	528
4	Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. <i>Hypertension</i> , <b>1997</b> , 30, 817-24	8.5	156
3	Nitric Oxide and Endothelial Regulation of Vascular Tone. <i>Methods in Neurosciences</i> , <b>1996</b> , 215-227		5

- 2 Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. *Circulation*, **1995**, 91, 139-44 16.7 197
- 1 HN-10200 causes endothelium-independent relaxations in isolated canine arteries. *Cardiovascular Drugs and Therapy*, **1992**, 6, 159-65 3.9 3